Literature DB >> 25592194

Change in medical spending attributable to diabetes: national data from 1987 to 2011.

Xiaohui Zhuo1, Ping Zhang2, Henry S Kahn2, Barbara H Bardenheier2, Rui Li2, Edward W Gregg2.   

Abstract

OBJECTIVE: Diabetes care has changed substantially in the past 2 decades. We examined the change in medical spending and use related to diabetes between 1987 and 2011. RESEARCH DESIGN AND METHODS: Using the 1987 National Medical Expenditure Survey and the Medical Expenditure Panel Surveys in 2000-2001 and 2010-2011, we compared per person medical expenditures and uses among adults ≥ 18 years of age with or without diabetes at the three time points. Types of medical services included inpatient care, emergency room (ER) visits, outpatient visits, prescription drugs, and others. We also examined the changes in unit cost, defined by the expenditure per encounter for medical services.
RESULTS: The excess medical spending attributed to diabetes was $2,588 (95% CI, $2,265 to $3,104), $4,205 ($3,746 to $4,920), and $5,378 ($5,129 to $5,688) per person, respectively, in 1987, 2000-2001, and 2010-2011. Of the $2,790 increase, prescription medication accounted for 55%; inpatient visits accounted for 24%; outpatient visits accounted for 15%; and ER visits and other medical spending accounted for 6%. The growth in prescription medication spending was due to the increase in both the volume of use and unit cost, whereas the increase in outpatient expenditure was almost entirely driven by more visits. In contrast, the increase in inpatient and ER expenditures was caused by the rise of unit costs.
CONCLUSIONS: In the past 2 decades, managing diabetes has become more expensive, mostly due to the higher spending on drugs. Further studies are needed to assess the cost-effectiveness of increased spending on drugs.
© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Year:  2015        PMID: 25592194     DOI: 10.2337/dc14-1687

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  31 in total

1.  Evaluating Digital Health Interventions: Key Questions and Approaches.

Authors:  Elizabeth Murray; Eric B Hekler; Gerhard Andersson; Linda M Collins; Aiden Doherty; Chris Hollis; Daniel E Rivera; Robert West; Jeremy C Wyatt
Journal:  Am J Prev Med       Date:  2016-11       Impact factor: 5.043

2.  The Burden of Obesity on Diabetes in the United States: Medical Expenditure Panel Survey, 2008 to 2012.

Authors:  Man Yee Mallory Leung; Nils P Carlsson; Graham A Colditz; Su-Hsin Chang
Journal:  Value Health       Date:  2016-11-04       Impact factor: 5.725

3.  Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review.

Authors:  Dongzhe Hong; Lei Si; Minghuan Jiang; Hui Shao; Wai-Kit Ming; Yingnan Zhao; Yan Li; Lizheng Shi
Journal:  Pharmacoeconomics       Date:  2019-06       Impact factor: 4.981

Review 4.  The rising cost of diabetes care in the USA.

Authors:  Patricia Peter; Kasia Lipska
Journal:  Lancet Diabetes Endocrinol       Date:  2016-05-04       Impact factor: 32.069

Review 5.  The Affordable Care Act and Diabetes Diagnosis and Care: Exploring the Potential Impacts.

Authors:  Rebecca Myerson; Neda Laiteerapong
Journal:  Curr Diab Rep       Date:  2016-04       Impact factor: 4.810

6.  Factors Contributing to the Rising National Cost of Glucose-Lowering Medicines for Diabetes During 2005-2007 and 2015-2017.

Authors:  Xilin Zhou; Sundar S Shrestha; Hui Shao; Ping Zhang
Journal:  Diabetes Care       Date:  2020-07-31       Impact factor: 19.112

Review 7.  Availability and Affordability of Essential Medicines: Implications for Global Diabetes Treatment.

Authors:  David Beran; Margaret Ewen; Kasia Lipska; Irl B Hirsch; John S Yudkin
Journal:  Curr Diab Rep       Date:  2018-06-16       Impact factor: 4.810

Review 8.  Advancing Health Policy and Program Research in Diabetes: Findings from the Natural Experiments for Translation in Diabetes (NEXT-D) Network.

Authors:  Mohammed K Ali; Frank Wharam; O Kenrik Duru; Julie Schmittdiel; Ronald T Ackermann; Jeanine Albu; Dennis Ross-Degnan; Christine M Hunter; Carol Mangione; Edward W Gregg
Journal:  Curr Diab Rep       Date:  2018-11-20       Impact factor: 4.810

9.  Trajectory of Excess Medical Expenditures 10 Years Before and After Diabetes Diagnosis Among U.S. Adults Aged 25-64 Years, 2001-2013.

Authors:  Sundar S Shrestha; Ping Zhang; Israel A Hora; Edward W Gregg
Journal:  Diabetes Care       Date:  2018-11-19       Impact factor: 19.112

10.  Financial Incentives and Diabetes Disease Control in Employees: A Retrospective Cohort Analysis.

Authors:  Anita D Misra-Hebert; Bo Hu; Glen Taksler; Robert Zimmerman; Michael B Rothberg
Journal:  J Gen Intern Med       Date:  2016-04-11       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.